The primary goal of this study is to evaluate the safety of a transcription factor decoy
targeting Signal Transducer and Activator of Transcription 3(STAT3) in patients with head and
neck cancer. The rationale for targeting STAT3 using this approach is to decrease
STAT3-mediated gene regulation. The study has the following scientific objectives:
1. To assess the safety of a single dose of intratumoral STAT3 decoy.
2. To estimate the effect of STAT3 decoy therapy on STAT3 activation levels, STAT3-mediated
gene expression, and apoptosis in treated tumors.